As per the agreement, Cerus will supply its 19 Intercept Illuminators through a Russian distributor.

The Intercept system inactivates viruses, bacteria and parasites present in donated blood and reduces the risk of transfusion-transmitted diseases.

The nucleic acid targeting mechanism of action inactivates hepatitis B and C, HIV, West Nile virus and bacteria, and also inactivates dengue, influenza and malaria pathogens.

Cerus president and CEO William Greenman said they expect these contracts will broaden the number of blood centers in Russia who can provide safer, Intercept-treated platelets and plasma.